Join us today and grab your seat for ICLE 2023
February 7th, 2023
Daniela Lopez de Luise
|
|
| |
| REGISTRATION IS NOW OPEN |
| |
|
We are delighted to announce that the registration for the 4th International Conference on Lymphocyte Engineering – ICLE 2023 is OPEN!
Don’t miss the conference where the world’s health innovators come together to discuss the latest developments and research findings in the field of immuno-gene therapy. Join us and become part of the only global community across industry and academia dedicated to lymphocyte engineering!
Benefit from our special savings rates by registering by 17 May 2023
|
| |
|
|
|
|
|
|
|
|
|
|
| BE THE CHANGE YOU WANT TO SEE IN MEDICINE |
| |
| If you have exciting and impactful new research in the field of lymphocyte engineering, grab the opportunity now and be part of ICLE 2023.
Having your abstract accepted for this year’s conference will provide invaluable benefits, here are a few of the top ones:
- Share the stage with the international experts and pioneers in the field. As a presenter of an accepted abstract for Oral Presentation, you will get a speaking slot in the main program sessions.
- Get your abstract nominated to be among the top ones and get a dedicated presentation. For a selected number of the accepted abstracts for Poster Presentation will be given the extra opportunity to present their research with a dedicated presentation at the ICLE research theatre.
- Win the voting for the Best Poster and present it on the main stage. One of the top abstracts selected for Poster Presentation will be chosen after voting by the ICLE participants during the conference days
- Get published in Human Gene Therapy Journal – all accepted abstracts, whose representatives have registered for the event will be published in the premier, multidisciplinary journal covering all aspects of gene therapy.
Go through the abstract topics, start working on your submission and be part of ICLE 2023!
Abstract submission deadline is 22 March 2023. |
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Both comments and pings are currently closed.
Posted in Congress 
